Media Summary: This presentation provided comprehensive guidance on CDER's nonclinical resources for approaching First-in-Human (FIH) ... This presentation provided information about the Small Business and Industry Assistance (SBIA) and its mission. Topics ... This presentation explored medical device coverage initiatives and the role of the Payor Communication Task Force in connecting ...

Fda Nih 2024 D1s05 Overview - Detailed Analysis & Overview

This presentation provided comprehensive guidance on CDER's nonclinical resources for approaching First-in-Human (FIH) ... This presentation provided information about the Small Business and Industry Assistance (SBIA) and its mission. Topics ... This presentation explored medical device coverage initiatives and the role of the Payor Communication Task Force in connecting ... This presentation explained the role and function of the Division of Industry and Consumer Education (DICE) within the This presentation provided guidance on nonclinical assessment of Cell and Gene Therapy (CGT) products to support IND ... This presentation discussed a rundown of the Do's and Don'ts from

This presentation outlined CDER's clinical considerations for First-in-Human trials and presented general good practices for FIH ... This presentation highlighted key clinical regulatory issues encountered during early-phase development of cellular and gene ... This presentation explored the essential components of Chemistry, Manufacturing, and Controls (CMC) within pharmaceutical ... This presentation demonstrated drug listing update and listing certification requirements, describing what information must be ... This presentation described drug listing requirements under 21 CFR 207 and identified common listing issues encountered during ... This presentation demonstrated creating a listing SPL through CDER Direct and enumerated data elements required for drug ...

This presentation explained the assignment of NDCs to drugs and described the history of the National Drug Code system. The first of three Q&A discussion panels from the This inaugural webinar was a collaborative effort between The last of three Q&A discussion panels from the This presentation addressed CBER's Chemistry, Manufacturing, and Control considerations for early phase studies of cell and ... The second of three Q&A discussion panels from the

Photo Gallery

FDA-NIH 2024 | D1S05 - Overview of CDER Nonclinical Resources and Guidance for Approaching First...
FDA-NIH 2024 | D1S02 - Overview of CDER’s Small Business & Industry Assistance (SBIA)
FDA-NIH 2024 | D1S15 - CDRH Medical Device Development Tools (MDDT) Program
FDA-NIH 2024 | D1S16 - Medical Device Coverage Initiatives: Connecting with Payors via the Payor...
FDA-NIH 2024 | D1S14 - How Can DICE Help You?
FDA-NIH 2024 | D1S11 - Nonclinical Assessment of Cell and Gene Therapy (CGT) Products to Support....
FDA-NIH 2024 | D1S03 - A Reflection on Today’s Seminar’s Title
FDA-NIH 2024 | D1S06 - CDER’s Clinical Consideration for First-in-Human Trials
FDA-NIH 2024 | D1S12 - Early Development of Cellular and Gene Therapy in Oncology -Clinical...
FDA-NIH 2024 | D1S04 - Chemistry, Manufacturing and Controls: Regulatory Considerations and Resource
eDRLS 2024 | D1S05-2 - Listing Updates and Blanket “No Changes” Certification Demo
GDF2025 – D1S05 - Request for Reconsideration_Process Overview and Best Practices for FDA Evaluation
Sponsored
Sponsored
View Detailed Profile
FDA-NIH 2024 | D1S05 - Overview of CDER Nonclinical Resources and Guidance for Approaching First...

FDA-NIH 2024 | D1S05 - Overview of CDER Nonclinical Resources and Guidance for Approaching First...

This presentation provided comprehensive guidance on CDER's nonclinical resources for approaching First-in-Human (FIH) ...

FDA-NIH 2024 | D1S02 - Overview of CDER’s Small Business & Industry Assistance (SBIA)

FDA-NIH 2024 | D1S02 - Overview of CDER’s Small Business & Industry Assistance (SBIA)

This presentation provided information about the Small Business and Industry Assistance (SBIA) and its mission. Topics ...

Sponsored
FDA-NIH 2024 | D1S15 - CDRH Medical Device Development Tools (MDDT) Program

FDA-NIH 2024 | D1S15 - CDRH Medical Device Development Tools (MDDT) Program

This presentation provided an

FDA-NIH 2024 | D1S16 - Medical Device Coverage Initiatives: Connecting with Payors via the Payor...

FDA-NIH 2024 | D1S16 - Medical Device Coverage Initiatives: Connecting with Payors via the Payor...

This presentation explored medical device coverage initiatives and the role of the Payor Communication Task Force in connecting ...

FDA-NIH 2024 | D1S14 - How Can DICE Help You?

FDA-NIH 2024 | D1S14 - How Can DICE Help You?

This presentation explained the role and function of the Division of Industry and Consumer Education (DICE) within the

Sponsored
FDA-NIH 2024 | D1S11 - Nonclinical Assessment of Cell and Gene Therapy (CGT) Products to Support....

FDA-NIH 2024 | D1S11 - Nonclinical Assessment of Cell and Gene Therapy (CGT) Products to Support....

This presentation provided guidance on nonclinical assessment of Cell and Gene Therapy (CGT) products to support IND ...

FDA-NIH 2024 | D1S03 - A Reflection on Today’s Seminar’s Title

FDA-NIH 2024 | D1S03 - A Reflection on Today’s Seminar’s Title

This presentation discussed a rundown of the Do's and Don'ts from

FDA-NIH 2024 | D1S06 - CDER’s Clinical Consideration for First-in-Human Trials

FDA-NIH 2024 | D1S06 - CDER’s Clinical Consideration for First-in-Human Trials

This presentation outlined CDER's clinical considerations for First-in-Human trials and presented general good practices for FIH ...

FDA-NIH 2024 | D1S12 - Early Development of Cellular and Gene Therapy in Oncology -Clinical...

FDA-NIH 2024 | D1S12 - Early Development of Cellular and Gene Therapy in Oncology -Clinical...

This presentation highlighted key clinical regulatory issues encountered during early-phase development of cellular and gene ...

FDA-NIH 2024 | D1S04 - Chemistry, Manufacturing and Controls: Regulatory Considerations and Resource

FDA-NIH 2024 | D1S04 - Chemistry, Manufacturing and Controls: Regulatory Considerations and Resource

This presentation explored the essential components of Chemistry, Manufacturing, and Controls (CMC) within pharmaceutical ...

eDRLS 2024 | D1S05-2 - Listing Updates and Blanket “No Changes” Certification Demo

eDRLS 2024 | D1S05-2 - Listing Updates and Blanket “No Changes” Certification Demo

This presentation demonstrated drug listing update and listing certification requirements, describing what information must be ...

GDF2025 – D1S05 - Request for Reconsideration_Process Overview and Best Practices for FDA Evaluation

GDF2025 – D1S05 - Request for Reconsideration_Process Overview and Best Practices for FDA Evaluation

This session provided a brief

eDRLS 2024 | D1S05-4 - Complying with Drug Listing Requirements

eDRLS 2024 | D1S05-4 - Complying with Drug Listing Requirements

This presentation described drug listing requirements under 21 CFR 207 and identified common listing issues encountered during ...

eDRLS 2024 | D1S05-1 - CDER Direct Drug Listing

eDRLS 2024 | D1S05-1 - CDER Direct Drug Listing

This presentation demonstrated creating a listing SPL through CDER Direct and enumerated data elements required for drug ...

eDRLS 2024 | D1S06-3 - NDC Assignment to Drugs

eDRLS 2024 | D1S06-3 - NDC Assignment to Drugs

This presentation explained the assignment of NDCs to drugs and described the history of the National Drug Code system.

FDA-NIH 2024 | D1S07 - Q&A Discussion Panel 1

FDA-NIH 2024 | D1S07 - Q&A Discussion Panel 1

The first of three Q&A discussion panels from the

FDA | NIH: Regulatory Do’s and Don'ts: Tips from FDA – CDER Segment

FDA | NIH: Regulatory Do’s and Don'ts: Tips from FDA – CDER Segment

This inaugural webinar was a collaborative effort between

FDA-NIH 2024 | D1S17 – Q&A Discussion Panel 3

FDA-NIH 2024 | D1S17 – Q&A Discussion Panel 3

The last of three Q&A discussion panels from the

FDA-NIH 2024 | D1S10 - CBER’s CMC Considerations for Early Phase Studies of Cell and Gene Therapy...

FDA-NIH 2024 | D1S10 - CBER’s CMC Considerations for Early Phase Studies of Cell and Gene Therapy...

This presentation addressed CBER's Chemistry, Manufacturing, and Control considerations for early phase studies of cell and ...

FDA-NIH 2024 | D1S13 – Q&A Discussion Panel 2

FDA-NIH 2024 | D1S13 – Q&A Discussion Panel 2

The second of three Q&A discussion panels from the